National addiction expert Kelly J. Clark, MD has joined the scientific advisory board of mission-driven psychedelic startup Journey Colab, Benzinga has learned exclusively.
Clark will support Journey’s drug development program and new model of addiction care that combines psychedelic science with psychotherapy and community support. Journey’s lead indication for FDA approval is Mescaline HCI (JOUR 100), a synthetic version of mescaline for the treatment of Alcohol Use Disorder. Mescaline, a classic psychedelic, targets serotonergic receptors found in the brain associated with addiction, mood, motivation, and perception.
